Isakov, Vasily http://orcid.org/0000-0002-4417-8076
Gankina, Natalia
Morozov, Viacheslav
Kersey, Kathryn
Lu, Sophia
Osinusi, Anu
Svarovskaia, Evguenia
Brainard, Diana M.
Salupere, Riina
Orlova-Morozova, Elena
Zhdanov, Konstantin
Funding for this research was provided by:
Gilead Sciences
Article History
First Online: 24 November 2017
Change Date: 23 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40261-021-01014-9
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Vasily Isakov has served on advisory committees or review panels for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., R-PHARM, and Vertex Pharmaceuticals. He has also served as a consultant for Bristol-Myers Squibb and Merck & Co., and on speakers’ bureaus for Bristol-Myers Squibb, Janssen Pharmaceuticals, R-PHARM, and Merck & Co. Kathryn Kersey, Sophia Lu, Anu Osinusi, Evguenia Svarovskaia, and Diana M. Brainard are employees and stockholders in Gilead Sciences. Riina Salupere reports personal fees from MSD/Merck, AbbVie, Jannsen, and grants from Intercept outside of the submitted work. Elena Orlova-Morozova has served as a speaker for Janssen-Cilag. Konstantin Zhdanov has served as an investigator for BMS, a speaker and advisor for Abbott, and as an investigator, speaker, and advisor for Gilead, AbbVie, Biocad, Janssen, MSD, Novartis, Roche, and R-Pharm. Natalia Gankina and Viacheslav Morozov have no discloses to declare.
: This phase IIIb study (NCT02472886) was sponsored by Gilead Sciences.